Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

NCT02508896 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

BIOLOGICAL: AFFITOPE® AT04A+adjuvant
BIOLOGICAL: AFFITOPE® AT06A+adjuvant
BIOLOGICAL: Adjuvant without active component

Sponsor

Affiris AG

Collaborators

[object Object]